Your new experience awaits. Try the new design now and help us make it even better

REVIEW article

Front. Pharmacol.

Sec. Experimental Pharmacology and Drug Discovery

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1632775

Machine Learning-Based Drug-Drug Interaction Prediction: A Critical Review of Models, Limitations, and Data Challenges

Provisionally accepted
  • 1George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Târgu Mureş, Târgu Mures, Romania
  • 2Universitatea Tehnica din Cluj-Napoca, ClujNapoca, Romania

The final, formatted version of the article will be published soon.

All possible interactions between drugs are not known, and accurately predicting interactions is even more difficult due to the complex nature of drug-drug interactions (DDI). Background/Objectives: New computational methods, based on statistical, machine learning, and deep learning techniques using drug-related entities (e.g., genes, protein bindings, etc.), help reduce the costs of in-vitro experiments through drug-drug interaction prediction (DDIp). This review examines recent advances in DDIp. It presents an in-depth review of the state-of-the-art studies relating to semi-supervised, supervised, self-supervised learning, and other techniques such as graph-based learning and matrix factorization methods for predicting DDIs. Methods: Of the 49 papers published in Web of Science in the last six years, 24 papers were considered relevant based on information presented in their titles and abstracts. The included articles focus specifically on predicting DDIs using a type of machine learning algorithm. Excluded articles focused on drug discovery, drug repurposing, molecular representation, or the extraction of biomedical interactions. The methodology, results limitations, and future research directions were studied for each paper. Common challenges, limitations, and future research directions were analyzed. Results and conclusions: The main limitations are class imbalance, poor performance on new drugs, limited explainability, and the need for additional data sources.

Keywords: Drug-Drug Interaction, adverse drug reactions, Machine learning techniques, healthcare, Semi-Supervised Learning, supervised learning, graph-based learning

Received: 21 May 2025; Accepted: 17 Jul 2025.

Copyright: © 2025 Gheorghita, Bocanet and Iantovics. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Laszlo Barna Iantovics, George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Târgu Mureş, Târgu Mures, Romania

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.